Market Cap (In EUR)
33.36 Million
Revenue (In EUR)
-
Net Income (In EUR)
279.84 Thousand
Avg. Volume
10.64 Thousand
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.17-1.88
- PE
- -
- EPS
- -
- Beta Value
- 0.307
- ISIN
- FI4000087861
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Antti Vuolanto D.Sc. (Tech)
- Employee Count
- -
- Website
- https://www.herantis.com
- Ipo Date
- 2014-06-11
- Details
- Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
More Stocks
-
OOA
-
MXF
-
MAV4
-
300323HC SemiTek Corporation
300323
-
SSPDLSSPDL Limited
SSPDL
-
ODL
-
601996
-
TCOR